Oncology devices market seen reaching $38.19B by 2030

The Business Research Company projects the next-generation oncology devices and solutions market will rise from $16.41 billion in 2025 to $19.46 billion in 2026, then nearly double again to $38.19 billion by 2030. Growth is being driven by higher cancer rates, wider use of molecular diagnostics and next-generation sequencing, and more demand for personalized cancer care.

Why it matters: - The market is expanding as cancer incidence rises and care shifts toward earlier detection, precision oncology, and individualized treatment. - The forecast points to sustained demand for advanced diagnostics, monitoring tools, and therapy platforms across hospitals and cancer centers. - The size of the opportunity is growing fast: the market is projected to move from $16.41 billion in 2025 to $38.19 billion by 2030.

What happened: - The Business Research Company released a 2026 market report on next-generation oncology devices and solutions. - The report estimates the market will climb from $16.41 billion in 2025 to $19.46 billion in 2026, a CAGR of 18.6%. - The report forecasts the market will reach $38.19 billion by 2030, with a CAGR of 18.4%. - The report says North America was the largest regional market in 2025. - The report covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company offered a free sample of the report and the full market report.

The details: - Next-generation oncology devices and solutions include technologies and instruments used to improve cancer detection, diagnosis, monitoring and treatment. - The market includes next-generation sequencing, digital pathology and targeted therapies. - The report links recent growth to rising global cancer incidence, broader access to molecular diagnostics, more sophisticated oncology testing tools, growth in hospital-based cancer care programs and wider use of targeted therapies. - The report points to additional growth drivers in personalized cancer treatment demand, genomic diagnostics investment, early screening expansion, artificial intelligence in oncology workflows and biomarker-guided cancer management. - Anticipated trends include wider adoption of precision oncology platforms, more use of next-generation sequencing for cancer diagnosis, growth in digital pathology, more personalized treatment strategies and stronger focus on early cancer detection. - The report says the field aims to improve patient outcomes by enabling faster and more precise interventions. - In January 2024, the American Cancer Society said cancer was expected to cause more than 611,000 deaths in the U.S., or more than 1,600 deaths per day.

Between the lines: - The forecast suggests oncology vendors are competing in a market where clinical need and technology adoption are rising at the same time. - North America’s lead likely reflects stronger healthcare infrastructure, research capacity and spending on advanced cancer care technologies. - The emphasis on AI, genomic diagnostics and precision oncology signals a market moving beyond standalone devices toward integrated data-driven care.

What's next: - The report expects market growth to continue through 2030 as screening, genomics and AI become more embedded in oncology workflows. - Hospital systems and cancer programs are likely to keep expanding demand for tools that support targeted and biomarker-guided treatment. - The Business Research Company says its 2026 reports also include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables.

The bottom line: - Cancer care is pushing the oncology device market toward faster growth, broader precision diagnostics and more personalized treatment platforms.